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Jennifer Lynn Lucado, MPH 
University of Pittsburgh, 2008
 
Methicillin-resistant Staphylococcus aureus (MRSA) is an infectious disease that has been a 
cause of nosocomial infections since the 1960s, but has more recently become an emergent 
disease in community settings.  MRSA infections that develop outside hospitals have been 
associated with risk factors such as young age, recent antibiotic use, recent contact with health 
care, and dermatological conditions.  To provide descriptive epidemiological data and evaluate 
potential risk factors, we undertook a case-control study of Allegheny County residents with 
laboratory-confirmed MRSA and methicillin-sensitive S. aureus (MSSA) cultures from January 
through August of 2007.  A random sample of each group was contacted and interviewed using a 
standardized questionnaire.  Comparing 54 MRSA culture-positive residents to 50 MSSA 
culture-positive residents, we found that having a reported self history of MRSA (p<.001), 
having a household member or self recently having been in the hospital (p=.041), and having a 
household member or self recently having been in a community living setting (p=.032) were 
significant risks of having a positive MRSA culture.  These findings have public health 
significance because as a greater number of people become infected or colonized by MRSA, the 
reservoir in the community will continue to grow, resulting in a greater number of infections and 
increased morbidity and mortality from the disease.       
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1.0  CHARACTERIZATION OF STAPHYLOCOCCUS AUREUS EPIDEMIOLOGY 
Staphylococcus aureus bacteria have a long-established history as a cause of human 
disease around the world.  Before the advent of antibiotic use, invasive S. aureus infections were 
almost always fatal (1).  The introduction of penicillin greatly improved prognosis for these 
serious cases of infection; however, resistant strains of bacteria appeared within a few years, due 
to bacterial production of β-lactamases. In 1960, methicillin was introduced as an alternative 
treatment for penicillin-resistant bacteria, but a mere six months after its introduction, a hospital 
in the United Kingdom reported methicillin-resistant S. aureus (MRSA).  Since then, MRSA has 
become a problem worldwide, causing much concern in the 1980s when it became the cause of 
many nosocomial infections.  In 1993, the epidemiology of MRSA became more complex when 
a genetically novel strain of community-associated MRSA (CA-MRSA) was reported.  
Previously, MRSA was only seen in people who had frequent contact with health care facilities.  
Residents of chronic-care facilities and people who had long or repeated hospital stays were the 
most likely to develop the infection (2). However, this first strain of CA-MRSA was discovered 
in indigenous populations living in Western Australia who had no previous contact with the 
health care system, a pattern of risk that is becoming increasing common in the United States 
today (3).       
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1.1 BACTERIAL INFORMATION 
1.1.1 Genetics 
S. aureus, a member of the Micrococcaceae family, has a circular chromosome about 
2800 bp in length that contains prophages, plasmids, and transposons.  Genes controlling 
virulence and resistance to antibiotics are found on both the chromosome and extrachromosomal 
elements.  These genes can be transferred between all types of gram-positive bacteria through 
extrachromosomal elements called plasmids (4).   
1.1.2 Methicillin resistance genes 
Methicillin resistance in S. aureus is due to the presence of the mecA gene.  The 2.1-kb 
mecA gene encodes the 78-kDa penicillin-binding protein (PBP) 2a (or PBP2’). PBPs are 
membrane-bound enzymes that catalyze the transpeptide reaction that is necessary for the cross-
linkage of the peptidoglycan chains that are a major component of the staphylococcal cell wall 
(5).  β-lactam antibiotics normally bind to PBPs in the cell wall, causing a disruption of the 
synthesis of peptidoglycan layer necessary for cell growth and resulting in cell death.  However, 
the PBP2’ protein has a low affinity for β-lactam antibiotics such as methicillin, so even in the 
presence of these antibiotics, peptidoglycan synthesis and normal cell wall growth will continue 
uninterrupted (1).   
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 Figure 1.  A schematic arrangement of SCCmec types I - V.  From Deurenberg et al. (6). 
 
The mecA gene is located on a mobile genetic element, known as the Staphylococcal 
Cassette Chromosome mec (SCCmec).  As shown in Figure 1, there are currently five main types 
of SCCmec that have been characterized, ranging in size from 20.9 to 66.9 kb.  The three shorter 
types, I, IV, and V, only encode resistance to β-lactam antibiotics.  Types II and III, however, 
encode additional types of antibiotic resistance through genes contained on integrated plasmids 
(pUB110, pI258, and pT181) and a transposon (Tn554).  Plasmid pUB110 provides resistance to 
kanamycin, tobramycin, and bleomycin; pI258 provides resistance to penicillins and heavy 
metals; and pT181 provides resistance to tetracycline.  Transposon Tn554 carries the ermA gene, 
which is responsible for the inducible macrolide, lincosamide, and streptogramin resistance (6).      
SCCmec also contains genes that regulate the mecA transcription and insertion sequences 
that allow it to integrate into the staphylococcal chromosome at a specific site within an open 
reading frame.  The regulation genes ensure that mecA is only transcribed in the presence of β-
lactam antibiotics; in their absence, the trans-membrane β-lactam-sensing signal-transducer 
MecRI waits to sense the presence of the antibiotics.  When β-lactam antibiotics are present, 
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MecRI is cleaved and the metallo-protease domain becomes activated, which, in turn, cleaves the 
MecI bound to mecA and allows mecA transcription (6).    
1.1.3 Panton-Valentine leukocidin 
Another element commonly found in MRSA is the Panton-Valentine leukocidin (PVL), a 
leukocytolytic toxin that has been associated with necrotic skin lesions and community-acquired 
pneumonia.  PVL is a member of the synergohymenotropic toxin family.  This is a family that 
also includes γ-hemolysin, a toxin produced by over 99% of S. aureus clinical strains.  Members 
of this family damage the membranes of host defense cells and erythrocytes via the synergistic 
effects of 2 non-associated classes of secreted proteins, designated class S and F; for PVL, these 
proteins are LukS-PV and LukF-PV.  LukS-PV and LukF-PV can cause damage by working 
with one another or by working with the γ-hemolysin S proteins (HlgA and HlgC) and F protein 
(HlgB), making 6 possible active pairs.  Any protein pair that includes one PVL protein has been 
shown to have necrotic effect on tissue, whereas, a pair consisting of only γ-hemolysin proteins 
will only have inflammatory effects (7).           
1.1.4 Lab methods for detection 
In order to positively identify the presence of S. aureus, laboratories must isolate a pure 
culture of the bacteria, looking for distinctively colored, circular, raised growths on the agar 
plate.  Colonial color may range from grey to yellow to orange, depending upon the amount of 
carotenoids present. Under the microscope, the bacteria have the appearance of non-motile, 
gram-positive clustered spheres.  Most strains of S. aureus are able to grow on 10% NaCl agar 
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and will aerobically produce acid from D-Mannitol and D-Trehalose, unlike their close relative 
S. epidermis, the other type of staphylococcus commonly found in humans.  Staphylococcus 
aureus will also test positive for coagulase and clumping factor (8).  To test for methicillin 
resistance, the Clinical and Laboratory Standard Institute (CLSI) recommends several different 
methods, including broth and agar dilution, disk diffusion, and agar screen methods.  All tests 
should be carried out at a maximum incubation temperature of 35°C and final readings should 
take place after 24 full hours of incubation.  Specific directives for these recommendations can 
be found in the CLSI document M100-S15 (1).    
1.2 CLINICAL MANIFESTATIONS 
Staphylococcus aureus is a major cause of skin, soft tissue, eye, respiratory, bone, joint 
and endovascular disorders, ranging in severity from localized and easily treatable to invasive 
and life threatening (4).  MRSA causes the same types of infections as methicillin-sensitive 
strains of S. aureus (MSSA). Extremely common clinical manifestations of MSSA and MRSA 
infections are skin and soft tissue infections.  Soft tissue abscesses, infections at wound sites, 
impetigo, cellulitis, and folliculitis are the most common outcomes of skin infection (9).  In the 
case of MRSA, abscesses are common; patients with abscesses frequently describe the start of 
infection as a “spider bite.”  This initial pustule is usually small in size and surrounded by 
cellulitis, but the infection often leads to abscess formation with progressive cellulitis, marked by 
tissue necrosis (10).    
In the eyes, most infections manifest as preseptal cellulitis and/or a lid abscess followed 
by conjunctivitis.  However, there are more serious cases involving corneal ulcers, 
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endophthalmitis, orbital cellulitis, and blebitis that have been observed, all of which are serious 
threats to sight (11).  The bacteria are also known to cause otitis media, or middle ear infection.  
In one case study, a child with a history of otitis media and bilateral tube placement was found to 
have MRSA as the causative agent of a severe infection (12).   
Most skin infections are localized and are a minimal threat to health.  However, 
infections can become invasive.  Invasive infections can result in bacteremia, endocarditis, acute 
osteomyelitis, and septic shock (13). In some cases of S. aureus bacteremia, especially in elderly 
patients, vertebral osteomyelitis may occur as a complication, resulting from staphylococci 
exiting the bloodstream and lodging themselves in previously damaged vertebra.  S. aureus is 
also the second most common cause of prosthetic joint infections, such as those of the hip or 
knee (14), and can cause septic arthritis (15).  MSSA and MRSA are also known to cause 
pneumonia, especially with ventilator use (16); MRSA stains containing PVL genes have been 
shown to cause necrotizing pneumonia (17).     
1.3 TREATMENTS AVAILABLE 
Treatments available for MRSA infection vary depending upon the site of infection and 
the antibiotic sensitivity of the particular strain.  In general, the incision and drainage of an 
abscess or removal of an infected medical device is the most important first step to treatment.  
Antibiotic selection, however, is also integral to successful treatment.  Recommendations for 
antibiotic selection vary, which is undoubtedly due, in part, to changes in additional drug 
resistances that have developed over time.  According to MRSA researcher B.A. Cuhna, research 
has shown that in vitro antibiotic susceptibility is not always predictive of in vivo susceptibility 
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of a particular strain. He asserts that trimethoprim-sulfamethoxazole (TMP-SMX) has shown 
variable results against MRSA, and that rifampin is known to be effective in treating 
staphylococcal infections, but has yet to be demonstrated effective against MRSA.  He 
recommends using five antimicrobial agents with consistently high demonstrated degrees of 
effectiveness in vivo against MRSA: quinupristin/dalfopristin, minocycline, daptomycin, 
linezolid, and vancomycin.  All of these are available in intravenous form, but minocyline and 
linezolid are both available in oral form, allowing patients to medicate at home at a low cost 
compared to the intravenous options (14).  However, serious, invasive infections are most often 
treated with intravenous vancomycin (18).    Another source recommends TMP-SMX or 
doxycyline as first-line agents and clindamycin and linezolid as second-line agents, noting that 
the second-line agents have high levels of inducible resistance (9).  TMP-SMX is commonly 
prescribed for treatment in outpatient settings, often in combination with rifampin, to minimize 
the likelihood of the development of resistance, and an estimated 95% CA-MRSA isolates are 
susceptible to the agent (19).  As with many other antibiotics used for the treatment of MRSA, it 
seems that TMP-SMX resistance is also becoming more common, especially in hospitals. In 
2004, it was estimated that 40% to 50% of MRSA isolates in Canadian hospitals were resistant to 
TMP-SMX treatment (20).  
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1.4 HUMAN COLONIZATION PATTERNS 
1.4.1 Colonization and the host response 
Staphylococcus aureus has long been known to colonize the human body.  Colonization 
has been defined in a number of ways, but most definitions have wording similar to the 
following: the presence of a microorganism not part of the normal flora of the host that is 
multiplying.  Colonization may or may not trigger a microbe-specific immune response in the 
host.  If a specific immune response occurs, the microbe could be eliminated; if not, disease may 
ensue and damage may occur.  As a result of this range of outcomes, colonization is observed in 
individuals for variable lengths of time (21).  In the first half of the twentieth century, researchers 
found that the anterior nares was the most consistent site of S. aureus colonization (22).  
However, cutaneous surfaces, conjunctiva, the intestinal tract, and the throat have since been 
found to be very common sites of colonization (23-25).  
1.4.2 Endogenous infection 
The most common threat evaluated regarding colonization is endogenous infection. In a 
hospital setting, it has been found that people who are nasal carriers are more likely to become 
infected with endogenous S. aureus.  Beginning in the late 1950s, researchers have also 
examined the link between S. aureus nasal carriage and surgical wound infections.  Comparing 
the rate of S. aureus infection of carriers to that of non-carriers, the risk ratios calculated in these 
studies range from 0.7 to 12.1, most likely due to differences in study populations (26).  Some 
relatively recent studies have focused on nasal carriage and bacteremia.  In one prospective study 
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conducted in Germany, 1278 patients were found to have nasal colonization with S. aureus upon 
hospital entry; of these patients, 14 (1.1%) subsequently developed S. aureus-caused bacteremia.  
In 12 of these 14 patients (86%), the bacterial strain found in the blood was a genetic match to 
the bacteria previously found in the nose (27).  So, while the risk of developing bacteremia is 
very small, the chances that bacteremia is caused by the same strain of bacteria that a patient was 
already colonized with is very great.  Another prospective study in the Netherlands found 
nosocomial S. aureus bacteremia to be three times more frequent in S. aureus carriers than in 
non-carriers, with 80% of carrier infections being endogenous.  However, the rate of S. aureus 
bacteremia-related deaths was significantly higher in non-carriers than in carriers.  This suggests 
that either the endogenous strains were less virulent than the exogenous strains or that carriers 
could be immunologically adapted to the S. aureus strain they carry, providing them with more 
adequate immune responses than non-carriers (28).   
1.4.3 Use of mupirocin for prevention of nasal colonization 
If nasal carriage of S. aureus can lead to infection, it follows that the elimination of 
carriage could lead to reduced rates of infection; as a result, many studies have been performed 
on the effects of local antibiotics or disinfectants.  Mupirocin (Bactroban) is one topical 
antibiotic that has shown promise in eliminating nasal carriage effectively in healthy people (26).  
In a randomized, double-blind placebo-controlled study (29), researchers founds that application 
to the nose twice daily for 5 days eliminated nasal carriage in 91% of stable nasal carriers, as 
illustrated in Figure 2.  Four weeks after the completion of treatment, 87% of the treatment group 
continued to be free of nasal carriage (compared to elimination in 7% of the placebo group).  At 
6 months post-treatment, the carriage rates in treatment and control groups were 48% and 72%, 
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respectively (30).  At 12 months post-treatment, the carriage rates in treatment and control 
groups were 53% and 76%, respectively.  For those who received treatment, 36% were colonized 
with a new strain of S. aureus at 12 months and 34% were recolonized by the strain they 
originally carried.  These studies also suggest that the hands are a primary site of S. aureus 
colonization because investigators found that 87% of S. aureus isolates from the participants’ 
hands were genetic matches of the isolates that had originally colonized the nose.  
 
Percentage of Healthy Carriers With S. aureus 
Nasal Carriage After Mupirocin Treatment
0
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Figure 2.  Nasal S. aureus colonization in healthy carriers after mupirocin treatment.  Adapted from 
Doebbeling et al. (29, 30). 
 
According to studies of patients with compromised immunity, mupirocin treatment 
eliminates S. aureus carriage with lower efficacy.  In one study of patients undergoing 
hemodialysis (31), the rate of carriage was reduced from 90% before treatment to 33% directly 
following treatment.  At 4 months post-treatment, the nasal carriage rate rose to 66%.  These 
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results suggest that elimination is less likely and that hemodialysis patients either have a greater 
number of alternate sites of colonization on their bodies or they are more likely to be recolonized 
from external sources than healthy people are.  
1.4.4 Person to person transmission 
Little is known about the means of spread for S. aureus colonization.  Colonized people 
are the most obvious reservoir from which the bacteria may be acquired.  One study found that 
nasal and/or intestinal colonization by S. aureus was correlated with an increased frequency of 
positive skin cultures on the patient, the surrounding environment, and the hands of patient care 
staff.  Patients with nasal or intestinal colonization were more likely than non-colonized people 
to have diarrhea, infection, and increased lengths of stay, which are all factors that could increase 
the likelihood of spread within a hospital (24).  Other studies have examined MRSA carriage in 
dialysis patients, health care workers and their families.  One study in Taiwan found a 
significantly higher rate of carriage in the immediate family of health care workers than in the 
immediate family of dialysis patients (32).  This speaks to the importance of hand washing that is 
often emphasized for preventing the spread of these bacteria, especially for health care workers 
after caring for each patient and before leaving work for the day.     
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2.0  A SHORT HISTORY OF MRSA          
In 1960, a mere six months after the introduction of methicillin as treatment for S. aureus, 
a hospital in southern England reported finding several isolates of MRSA (33).  Initially, this 
appeared to be a unique occurrence and microbiologists were optimistic of the continued 
effectiveness of methicillin; however, by 1967, MRSA had also been reported in Switzerland, 
France, Denmark, Australia, and India.  After the initial appearance of MRSA throughout the 
continent, Europe saw a rise and then fall, for unknown reasons, in the prevalence of MRSA 
through the early 1980s.  In the 1980s, however, concerns about MRSA rose again when multi-
drug resistant MRSA was reported in Ireland, the United Kingdom, and the US; one particular 
strain was suspected to have spread from an outbreak in Australia to cause an outbreak the 
United Kingdom (3).  
For many years, the only cases of MRSA found in the community were in people who 
had frequent contact with health care facilities (3). However, in 1993, a strain of MRSA 
genetically distinct from the known hospital strains was discovered in indigenous people living 
in Western Australia who had no previous contact with the health care system (34).  In the 
United States, an increasing number of CA-MRSA cases were noted in the late 1990s.  This 
caused a scare because people who were otherwise healthy and had with little contact with the 
health care system were hospitalized or died from MRSA.  In 1998, a group of Chicago 
researchers described 26 children hospitalized for community-associated MRSA who lacked 
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traditional health care-associated risk factors (35). Since then, the number of MRSA cases 
reported in the community has increased greatly.  Clusters of MRSA infection have been 
investigated among children, newborns, athletes, military personnel, prisoners, and tattoo 
recipients (36-41).  Despite these investigations, the public health community still lacks a clear 
epidemiological picture of the disease. 
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3.0  EPIDEMIOLOGY OF MRSA 
3.1 DEFINITIONS OF HA-MRSA VERSUS CA-MRSA 
One of the greatest challenges in MRSA investigations is simply differentiating between 
hospital and community cases of the infection.  One variation in wording is the use of “hospital 
associated,” “hospital acquired,” or “HA” versus using the word “nosocomial.”  Community 
cases may be referred to as “community associated,” “community acquired,” “community 
onset,” “community derived,” or “CA.”  For the purposes of their Active Bacterial Core 
Surveillance Program, the CDC has defined a community-associated MRSA (CA-MRSA) case 
as a patient with a MRSA infection and no history of the following: surgery, hospitalization, 
residence in a long-term care facility, or dialysis within one year prior to infection; presence of a 
percutaneous device or indwelling catheter; hospitalization >48 hours before the culture; or 
history of previous MRSA infection or colonization (42).  Conversely, a case of HA-MRSA can 
be defined as any MRSA infection that does not qualify as CA-MRSA.   
Many studies have used the term, “community acquired” to classify the cases of 
infection, with the main criteria for selection being the development of MRSA infection while 
being outside of the hospital or developing it within 48 hours of hospitalization.  The term 
implies that the bacteria causing the infection were acquired in the community, outside of 
hospital settings.  The problem with this classification, however, is that people may develop a 
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MRSA infection outside of the hospital setting, but may have acquired the bacteria during a 
recent hospital stay.  These patients would not be differentiated from patients lacking a history of 
hospitalization because risk factors were not assessed.  Thus, HA-MRSA cases would be 
included in the counts of community-acquired MRSA cases. CA-MRSA can also become 
ambiguous when it is defined by genetic or endotoxin presence.  This is a problem because some 
strains of MRSA that have genetic characteristics traditionally associated with CA-MRSA are 
presenting in hospitals, which creates a very fine line between genetically-defined HA-MRSA 
and CA-MRSA.  In this thesis, the only categories referred to will be CA-MRSA and HA-
MRSA.  CA-MRSA will always refer to “community-associated MRSA” and HA-MRSA will 
refer to “hospital-associated MRSA,” taking into account the time and place of infection 
development, rather than the genetic makeup of the bacteria.  For the most part, the 
characterization of CA-MRSA does not exclude patients with health care contact risk factors that 
would cause them to be excluded by the CDC definition.           
3.2 PREVALENCE OF NASAL CARRIAGE 
As previously stated, S. aureus is a very common colonizer of humans.  As part of the 
CDC’s comprehensive National Health and Nutrition Examination Survey 2001-2002, nasal 
samples were obtained from a representative sample of the United States (US) population and 
tested for the presence of S. aureus and MRSA (22).  From these results, it was estimated that 
32.4% (95% confidence interval [CI], 30.7%-34.1%) of the US population is nasally colonized 
with S. aureus and 0.8% (95% CI, 0.4%-1.4%) is nasally colonized with MRSA.  The greatest 
prevalence of S. aureus colonization was observed in children aged 6 to 11.  MRSA colonization 
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was associated with the age of 60 years or greater and being female, but was not associated with 
recent health care exposure.  Other than this nasal data, not much is known about the prevalence 
of colonization for other areas of the body.  As previously explained, some colonization studies 
show that people may be colonized in other common external locations, such as the throat (25) or 
skin (12), without concurrent colonization in the nose.  Thus, the prevalence estimates based 
solely on nasal colonization may be an underestimate of population prevalence. 
3.3 COMPARISON OF HA-MRSA VERSUS CA-MRSA EPIDEMIOLOGY 
3.3.1 Hospital-Associated MRSA epidemiology 
3.3.1.1 Trends    
3.3.1.1.1 Geographic variability 
The prevalence of HA-MRSA varies greatly by geography.  The European Antimicrobial 
Resistance Surveillance System (EARSS) is responsible for monitoring the prevalence of MRSA 
and changes over time in most European countries.  From 1999 through 2002, they collected 
50,759 nosocomial isolates from 495 hospitals in 26 countries.  Researchers found large 
variations in the incidence of MRSA between countries and sometimes between hospitals within 
a country.  In some northern countries, such as Sweden and Denmark, the prevalence was less 
than 1%; in some southern countries, such as Greece and Italy, and the United Kingdom (UK), 
the prevalence was upwards of 40%.  Variation within countries was greatest in countries with 
prevalence between 5% and 20%.   
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 Figure 3.  Geographic variation in proportions of MRSA detected by EARSS (1999 - 2002).  From Tiemersma 
et al. (43). 
 
3.3.1.1.2 Rise in prevalence of MRSA isolates 
EARSS also observed that some countries had statistically significant changes in the 
percentage of cases during the study period.  The UK saw the greatest percentage increase, from 
30.5% in 1999 to 44.5% in 2002.  Slovenia was the only country to show a significant decrease, 
declining from 22.3% to 14.7% (43).  In the US and some Asian countries, an increase in HA-
MRSA has also been observed.  One study based in a large Taiwan university hospital found the 
prevalence of MRSA isolates increased from 26.7% of nosocomial infections in 1990 to 77% in 
2001; as an incidence rate, 8.9 per 100,000 discharges from the hospital in 1990 had HA-MRSA, 
but 32.6 per 100,00 had it in 2000 (44). 
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3.3.1.1.3 Estimation for incidence of invasive MRSA 
Recently, an attempt was made to characterize life-threatening MRSA cases in the US.  
In 2007, information was released from the Active Bacterial Core surveillance system on the 
incidence of invasive HA-MRSA infections in several geographic areas.  Researchers found that 
of all invasive cases of MRSA in these cities, 85% were health care-associated; specifically, 
26.6% developed in the hospital and 58.4% developed outside of the hospital.  As with the 
EARSS data, incidence variation by geography was also observed in this study.  HA-MRSA that 
developed while in the hospital, for example, ranged from 6.1 per 100,000 persons for Ramsey 
County, Minnesota to 19.7 per 100,000 persons for Baltimore City, Maryland (13). 
3.3.1.1.4 Threat to intensive care unit patients 
MRSA infections are a common problem for patients in intensive care units (ICUs).  
Patients in the ICU are those with the most life threatening conditions. Because of this stress on 
the body, ICU patients are at great risk of HA-MRSA infection because a combination of 
lowered immune response and the utilization of many medical devices, such as catheters and 
mechanical ventilation, that can serve as additional sites of colonization and entryways into the 
body. In the ICU, it is estimated that 20% of patients are colonized or will become colonized 
with MRSA during their stay (45). The percentage of S. aureus isolates that were MRSA in ICUs 
from 1998 to 2002 was 48.5%, and in the year 2003, the proportion of MRSA isolates in ICUs 
increased by 11% to 59.5% (46).  Historically, it is estimated that the percentage of MRSA 
isolates in ICU patients has increased from 29% in 1989 to over 60% in 2002 (45).  In the 
general hospital patient population, MRSA rates are likewise high.  According to one report by 
the National Nosocomial Infections Surveillance System (NNISS), from January 1998 through 
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June 2003, 42% of S. aureus isolates in non-ICU patients were MRSA (47).  However, the rates 
are still slightly higher in ICUs.  
3.3.1.2 Common strains of HA-MRSA detected 
In the US, the most MRSA strains most commonly found to be associated with hospitals 
include pulsed field gel electrophoresis (PFGE) patterns USA100, USA200, and USA800.  The 
USA100 strain is the most prevalent strain by far; it is estimated that 43% of MRSA can be typed 
as USA100 (48).  The prevalence of other strains is shown below in Figure 4. 
 
Percentage of Total MRSA Isolates
USA100
43%
Other
7%
USA400
6%
USA200
9%
USA800
7%
USA300
14%
USA500
5%
USA600
3%
USA700
6%
 
Figure 4.  MRSA strains by percentage of prevalence in the US.  Adapted from McDougal et al. (48). 
 
In HA-MRSA strains, genetic elements vary by isolate.  Hospital associated isolates have 
been found to most commonly carry SCCmec types I, II, and III (49). SCCmec types II and III 
are both larger elements that have the ability to provide resistance to additional antibiotic types, 
so HA-MRSA has commonly been associated with multi-drug resistance (50).  The prevailing 
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type of SCCmec found in HA-MRSA isolates is II, but prevalence varies geographically.  At a 
military hospital in San Diego, 94% of HA-MRSA isolates contained SCCmec type II (51).  In a 
Minnesota study, 81% of HA-MRSA isolated carried SCCmec type II (50).  In San Francisco, 
however, among HA-MRSA strains in hospitals, about 48% carried type II.  The remaining 52% 
carried SCCmec type IV, which is commonly found in CA-MRSA, suggesting that a reservoir of 
CA-MRSA was well established in the community and has the ability to move into the hospital 
setting. Interestingly, in San Francisco long-term care facilities, 81.6% of MRSA strains carried 
SCCmec type II, similar to the Minnesota figures (52).   
3.3.1.3 Common clinical manifestations of HA-MRSA 
 HA-MRSA is known to cause a wide range of infections and is more likely than CA-
MRSA to cause invasive infections.  In one study, investigators collected data on HA-MRSA 
infections from 1990 to 2004 and found that MRSA was responsible for the infection of sites 
listed with the frequencies shown in Table 1 (51).  Sites covered in the “other” category included 
samples from body fluids, bone, and heart valves, indicating invasive infection types.  For HA-
MRSA, skin and soft tissue infections are often at surgical site incisions (SSIs).  In fact, it was 
estimated by a 2003 study that 29% of culture positive SSIs were caused by MRSA (53).  Other 
major infection types that are more common to HA-MRSA than CA-MRSA include respiratory 
and urinary infections.  As shown in Table 1, Crum and her colleagues found in their research 
that 19% of MRSA infections were in the lungs (sputum) and 12.3% were in the urine.  
However, that study was based out of a military hospital, so the results might not be typical of a 
hospital serving the general public.  Other studies have found higher proportions of these 
infection types.  In a San Francisco study, estimates for the percentage of MRSA infections in 
hospitals that were respiratory and urinary were 31.6% and 17.6%, respectively (52). The 
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proportion of MRSA infections affecting the urinary tract might be more common in long term 
care facilities; in San Francisco, 29.6% of MRSA cases were urinary (52).  For respiratory 
infections—pneumonia specifically—MRSA has been estimated to be responsible for 22.9% of 
hospital-associated pneumonia cases.  Ventilator-associated pneumonia (VAP) has always been a 
threat to ICU patients and now MRSA is increasingly the cause of VAP.  One study in press 
found that 14.6% of VAP was caused by MRSA (54). 
 
Table 1.  Frequency of distribution of HA-MRSA infection by site.  Adapted from Crum et al. (51). 
  HA-MRSA Cases 
Site of Infection n=457 
Soft tissue/abscess 218 (47.7%) 
Sputum 87 (19.0%) 
Blood 71 (15.5%) 
Urine 56 (12.3%) 
Catheter/foreign device 52 (11.4%) 
Multiple simultaneous sites of infection 45 (9.8%) 
Other 19 (4.2%) 
Ear/nose/sinus/throat 12 (2.7%) 
Cerebrospinal fluid 3 (0.7%) 
Not documented 1 (0.2%) 
 
3.3.1.4 Risk factors for HA-MRSA 
Some pre-existing conditions have been found to increase the likelihood of HA-MRSA 
infection.  Chronic medical illnesses are one example.  Patients undergoing hemodialysis 
treatment and patients with HIV infection are two groups at higher risk for infections of all 
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kinds, including MRSA (45). Many patients undergoing hemodialysis have chronic renal failure, 
a condition associated with reduced chemotaxis and phagocytosis that results in an impaired 
immune system.  Combine that effect with higher observed rates of skin and nasal colonization 
by S. aureus in dialysis patients and the repeated penetration of the skin barrier required for 
treatments, and the increased infection rate seems to be a likely outcome (31).  The biggest risk 
for developing infection, though, is carriage of the bacteria.  In Sista’s review of S. aureus 
infections in ICU patients, a summary of risk factors for carriage was reported (Figure 5) (45).  
One study looking at colonization found that 44% of ICU patients who were colonized with 
MRSA went on to develop MRSA infections.  However, they also found that 40% of infected 
patients were colonized and infected in the same day, which could explain why colonization has 
not always been found to precede infection (55).    
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 Figure 5.  Risk factors for methicillin-resistant Staphylococcus aureus carriage.  From Sista et al. (45).  
Reprinted from Anesthesiology Clinics of North America, Vol 22, RR Sista, G Oda, and J Barr, Methicillin-
resistant Staphylococcus aureus infections in ICU patients, Pages 405-435, Copyright (2004), with permission 
from Elsevier.    
 
3.3.1.5 HA-MRSA contributions to increased morbidity and mortality 
Obviously, any type of infection can cause an increase in morbidity and mortality.  
However, many studies have been conducted that compared the outcomes of patients infected 
with MRSA to patients infected with MSSA, each focusing on a specific infection type.  In the 
case of SSIs, Engemann and colleagues found that patients with MRSA had a greater 90-day 
mortality rate and a greater length of hospitalization after the start of infection compared to 
patients with MSSA SSIs.  In fact, the 90-day mortality adjusted odds ratio for MRSA versus 
MSSA patients with SSIs was 3.4 (95% CI, 1.5-7.2) and the median number of days hospital stay 
after infection was 15 days in MRSA patients versus 10 days in MSSA patients (56).  In a 
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comparison of bacteremic patients, numerous increases in morbidity and mortality were found.  
MSSA bacteremic patients had longer ICU stays and ventilator dependency, a higher 30-day 
mortality rate (53% vs. 18%), and a higher in-hospital mortality rate (64% vs. 24%) than MSSA 
patients.  With the data collected, the attributable mortality rates were calculated for MRSA 
bacteremia (23.4%) and MSSA bacteremia (1.3%); thus, MRSA bacteremia was found to have a 
significantly higher mortality rate (57).  Similarly, a meta-analysis of ICU bacteremias found that 
patients with MRSA were two times as likely as patients with MSSA to die of bacteremia, with a 
risk ratio of 2.12 (58).  The impact of MRSA in pneumonia patients has also been examined, but 
with conflicting results (45).  Some studies have shown no increase in infection-related 
mortality, while others have shown a twenty-fold increase in risk (16, 59).  It appears that the 
course of treatment may be key in reducing the risk in mortality for hospitalized MRSA 
pneumonia patients.  In the study that found equal risks of mortality, a majority of patients were 
given vancomycin.  However, in the study that found MRSA to be twenty times more deadly, β-
lactam antibiotics were used to empirically treat patients until antibiotic sensitivity results came 
back.  Vancomycin, while effective in treating both MSSA and MRSA, is known to have poor 
penetration of pulmonary tissues and slow bactericidal effects.  On the contrary, β-lactam 
antibiotics are only effective for MSSA but have no problem penetrating pulmonary tissues and 
have average bactericidal effects (45).  Thus, by administering vancomycin as a first-line agent 
for S. aureus pneumonia, physicians are helping MRSA patients gain effective treatment in a 
timely manner, but are not providing MSSA patients the most beneficial treatment. 
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3.3.2 Community-Associated MRSA epidemiology 
3.3.2.1 Trends 
3.3.2.1.1 Affected populations 
In 1982, the first CA-MRSA outbreak was reported in the US (60).  In a Detroit hospital 
from March to December of 1980, a group of physicians noticed a spike in MRSA infections that 
developed outside of the hospital.  After some investigation of risks, they found that, of the 40 
patients infected, 24 were intravenous (IV) drug users.  However, it was not until the 1990s that 
CA-MRSA clusters were observed in other special population groups.  It was during this period 
that outbreaks of infection became commonly observed among young children, Native American 
and Pacific Islander communities, prisoners, military personnel, men who have sex with men, 
and participants in professional and amateur sports (61). 
3.3.2.1.2 Incidence estimates 
Some relatively recent attempts to estimate the incidence of MRSA have been made, both 
in the US and abroad, but with the number of risk factors needed to exclude the HA-MRSA cases 
from the calculations, this can be a real challenge.  In the United Kingdom (UK), however, 
where a socialized system of medical care allows investigators full access to 3.4 million patients’ 
medical records that detail medical history and treatments received, it was estimated that in the 
adult population (aged 18 and over), the average incidence of CA-MRSA from 2000 to 2004 was 
15.2 cases per 100,000 persons per year.  Investigators noted an increase from 332 cases in 2000 
to 484 cases in 2004 (62).  Here in the US, a multi-location surveillance of invasive CA-MRSA 
was completed in 2005.  In the US, it appears that invasive CA-MRSA varies hugely by 
geography; of the 9 locations reporting, the lowest incidence was found in Ramsey County, 
Minnesota, at 1.6 persons per 100,000 and the highest incidence was in Baltimore City, 
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Maryland, at 29.7 per 100,000.  However, Baltimore was a great outlier compared to the other 
locations, which ranged from 1.6 to 6.8 per 100,000; thus the overall estimate for invasive CA-
MRSA for these sites was 4.6 per 100,000 (interval estimate, 3.6-4.4) (13).  Because the different 
criteria that were used to classify cases in the UK and US, with the UK having much better 
access to detailed medical history information used to ensure strict adherence to case definition, 
the two incidence rates cannot be compared. 
3.3.2.1.3 Increases in jails and general population 
There are many documented CA-MRSA outbreaks in the prison population.  In a review 
of MRSA in prisoners, Aiello and colleagues found that San Francisco and Texas jails had 
reported similar large increases in methicillin-resistance over time (63).  In San Francisco, the 
prevalence of MRSA among S. aureus isolates rose from 29% in 1997 to 74% in 2002.  In 
Texas, the prevalence of MRSA among prisoners with S. aureus infections increased from 25% 
in 1998 to 66% in 2002.  Interestingly, this increase in MRSA was also observed in a 
comprehensive study of the general population in the San Francisco area (52).  In this study, 
investigators found that the number of unique MRSA isolates increased from 160 in 1996 to 563 
in 2002.  The number of HA-MRSA cases in hospitals and long term care facilities remained 
stable over this time; it was the CA-MRSA cases that had increased significantly, as shown 
below in Figure 6.  In fact, it was calculated that 82% of the MRSA cases above the baseline 
could be attributed to CA-MRSA infection.    
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 Figure 6.  Estimated number of MRSA isolates from 1996 to 2002 in the San Francisco area, where 
CO is CA-MRSA, NO is HA-MRSA associated with hospitals, and LTCF is HA-MRSA associated with long 
term care facilities.  From Carleton et al. (52).  
 
3.3.2.1.4 Increase in pediatric cases 
Looking at CA-MRSA in children, an increasing trend is also shown.  MRSA is a 
common infective agent seen in children seeking emergency care.  At a Texas children’s hospital 
emergency department from 2001 to 2004, the number of CA-MRSA infections increased by 
2.2-fold; comparatively, CA-MSSA cases increased 1.7-fold.  However, there were many more 
MRSA cases and than MSSA cases.  Of the S. aureus isolates from community-associated 
infections during this three year surveillance period, 74% were MRSA (2659/3578).  Researchers 
also observed a statistically significant increase in the proportion of MRSA isolates over those 
three years.  In year one, 71.5% were MRSA, in year two, 73.5% were MRSA, and in year three, 
76.4% were MRSA (p=.008) (64).  From these observations in children and those in prisoners, 
the implications are that a reservoir of MRSA that is genetically distinct from common hospital 
strains exists in the community.  In the late 1990s, there were two clusters of MRSA infection 
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among children lacking health care-associated risk factors—one in Chicago and one in 
Minnesota and North Dakota—that have given the community reservoir theory greater weight 
(35, 36).     
3.3.2.2 Common strains of CA-MRSA detected 
The PFGE strain most often associated with CA-MRSA cases is USA300, but USA400, 
700, 1000, and 1100 have also been found to be causes of infections (13, 48).  An overwhelming 
majority of CA-MRSA infections are caused by strains carrying SCCmec IV, one of the shorter 
SCCmec variations that is much less likely to carry multi-drug resistance (54).  Many CA-MRSA 
strains also carry PVL genes. Both of these genetic elements have been shown to have a strong 
association with CA-MRSA infections and are not often present in HA-MRSA isolates.  In a 
comparison of CA-MRSA to HA-MRSA isolates, odds ratios were calculated for the presence of 
SCCmec IV and PVL, yielding 5.87 (95%CI, 3.67-6.55) and 5.01 (95%CI, 3.49-5.25) 
respectively (50).  One investigation showed that 95% of the CA-MRSA isolates in a particular 
health care system contained SCCmec type IV and 69% carried PVL genes (51).  This genetic 
epidemiology explains why CA-MRSA infections have widely been characterized as causing 
skin infections and not having multiple drug resistance problems (19). Figure 7 shows a 
summary of characteristics used to distinguish CA-MRSA from HA-MRSA that was published 
to educate health care professionals.  
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 Figure 7.  Summary of distinguishing characteristics for HA-MRSA and CA-MRSA.  From Ragan (19).  
(Used with permission from JAAPA, Journal of the American Academy of Physician Assistants. Copyright is 
held by the American Academy of Physician Assistants and Haymarket Medical, Inc.)   
 
Although CA-MRSA strains vary by geographic location, it appears that CA-MRSA 
strains have become less genetically diverse over time, with some strains dominating others 
because of environmental selective pressures (51).  Kaplan and colleagues suggest that these 
selective pressures might lead to changes in a short period of time (64).  In early 2000, they 
observed that roughly 50% of CA-MRSA isolates were USA300, but by 2003, more than 90% of 
CA-MRSA isolates were USA300.  Others have also noted the emergence of a dominant MRSA 
clone in a community, so it may be a common phenomenon (65, 66). 
3.3.2.3 Common clinical manifestations of CA-MRSA 
The most common manifestation of CA-MRSA reported, by far, is skin and soft tissue 
infection (SSTI).  Estimates of the percentage of CA-MRSA cases that are SSTI range from 
59.3% (52) to 95.6% (64).  However, most estimates fall somewhere between 75% and 80% (2, 
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15, 18, 50).  Within the SSTI category, the most common type of infection observed is abscess.  
Of the CA-MRSA SSTIs seen at a Texas children’s hospital, 59% were classified as abscesses 
(67); identically, in a three city study, a figure of 59% was also calculated from observations 
(15).  However, cellulitis, folliculitis, and wound infections are also possible, with cellulitis 
being the second most common SSTI (15).  CA-MRSA can also cause pneumonia, sometimes 
preceded by influenza-like illness (54).  In one surveillance effort, it was estimated that 
pneumonia may comprise 2% of all CA-MRSA cases (15).  In 2005, four cases of severe 
necrotizing CA-MRSA pneumonia were reported in Baltimore, Maryland (68).  All four patients 
were previously healthy adults lacking typical risk factors for MRSA infection, and all were 
infected by the USA300 PFGE type with SCCmec IV and PVL genes.  These were the first cases 
of this type reported in North America.  Other types of infection possible but not as novel as 
necrotizing pneumonia include urinary and respiratory infections, which are estimated to 
represent about 9% and 12% of CA-MRSA cases, respectively (52).  A small estimated 
percentage of CA-MRSA cases, 6%, are invasive, which includes bacteremia, septic arthritis, 
and osteomyelitis (15). 
3.3.2.4 Risk factors for CA-MRSA 
Ironically, the people found to be most at risk of developing a CA-MRSA infection are 
young and healthy people who lack health care risk factors.  Studies comparing people infected 
with CA-MRSA versus people with HA-MRSA have consistently found that CA-MRSA patients 
are significantly younger.  In particular, a study by Crum and colleagues found that CA-MRSA 
patients had a median age of 22 years, compared to the median age of 64 years observed in HA-
MRSA patients (51).  But, considering this data was collected from a military hospital, serving a 
large population of younger people and their families, these figures may not be generalizable to 
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other populations.  In another study with a broader population, investigators found the median 
age to be 23 for CA-MRSA patients compared to a median age of 68 years for HA-MRSA 
patients (50).  Even when cases from the two participating pediatric hospitals were excluded 
from the analysis, the median age of CA-MRSA patients was still significantly lower than HA-
MRSA patients (30 versus 70 years, p<0.001).   
In addition to age, race has also been compared between people with CA-MRSA and CA-
MSSA. In a study by a group in Texas, it was found that African American children represented 
a disproportionately high number of CA-MRSA cases (67).  When the group looked more 
closely at demographic characteristics for the racial groups, they saw no significant differences 
in type of health insurance, proportion attending day care, chronic illness, use of antibiotics 
within the previous six months, previous hospitalization, or exposure to health care workers or 
nursing home residents.  Thus, little explanation has been given on why this difference exists.  
Later studies would replicate these results.  In another Texas study at the same children’s 
hospital, investigators found once again that African American children were more likely than 
children of other racial groups to develop CA-MRSA, as shown in Table 2 below (64). In an 
Atlanta study, incidence rates were also found to be significantly higher in African Americans 
than in whites (RR=2.74, 95%CI 2.44-3.07) (15). 
   
Table 2.  Racial and ethnic distribution of cases of CA-MRSA and CA-MSSA. Adapted from Kaplan et al. 
(64). 
  MRSA MSSA 
Patient Race/Ethnicity Total Number, (%) Total Number, (%) 
Asian 34 (1.3%) 33 (3.6%) 
African American 1045 (39.3%) 249 (27.1%) 
White  681 (25.6%) 259 (28.2%) 
Hispanic 788 (29.6%) 302 (32.9%) 
Other  86 (3.2%) 60 (6.5%) 
Unknown 25 (0.9%) 16 (1.7%) 
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Underlying health conditions among CA-MRSA patients have been examined for 
commonalities.  In children, the most common underlying condition is a dermatological 
condition.  Of CA-MRSA cases in two studies, researchers found that 9% of children had 
eczema or some other dermatological condition (50, 67).  Another underlying condition that is 
commonly reported, about as often as dermatological conditions, is asthma (15, 67).  However, 
Sattler and colleagues found that asthma was reported as frequently in the MSSA patients, 
suggesting that it does not play a significant role in increasing risk of MRSA.  In adults with CA-
MRSA infections, the underlying conditions reported most often are tobacco use (19-35%) and 
diabetes (17-19%) (15, 50).  However, while tobacco use is reported, there have been no 
suggestions that it increases the general risk of CA-MRSA infection.  Close behind tobacco use 
and diabetes comes the risk increase due to previous skin infection or dermatological conditions.  
Naimi and colleagues found that 13% of cases had dermatological conditions (50), and Fridkin 
and colleagues found that 21% of cases had previous skin infection (15).   
It has also been suggested that previous antibiotic use may lead to increased risk of CA-
MRSA infection.  One study from the UK found an apparent dose-dependent relationship 
between antibiotic use and infection that varied by antibiotic class (62).  The strongest increase 
in risk was found with quinolones (adjusted OR=3.37, 95%CI 2.80-4.09) and macrolides 
(adjusted OR=2.50, 95%CI 2.14-2.91).  These findings are somewhat supported by a recent 
meta-analysis that examined previous antibiotic use as a risk factor for MRSA infection (69). In 
the meta-analysis, it was calculated that quinolones provided the highest increase to risk of 
infection (RR=3, 95%CI 2.5-3.5); macrolides were only found to increase risk in one study 
evaluated by the authors, so they were not reported as a risk factor.  Also in the meta-analysis, a 
risk ratio was calculated for general antibiotic use in raising the risk of CA-MRSA and was 
 32 
found to be 1.6 (95%CI 1.5-1.7).  Despite this evidence of antibiotic use as a risk factor, though, 
investigators in the UK study noted that a great percentage (38.9%) of patients included in this 
study who developed CA-MRSA infection had not taken antibiotics in the year before their 
infections.   
General exposure to health care has also been identified as a potential risk factor for 
developing CA-MRSA.  By the CDC-recommended definition, for a case to be considered 
community associated, the patient cannot have been hospitalized in the past year (42).  However, 
some surveillance efforts classify by the time of sample collection only, defining CA-MRSA as 
an infection developing in an outpatient setting or within 72 hours of admission to the hospital.  
In one study using this loose definition, Carleton and colleagues found that 65.2% of CA-MRSA 
patients had been hospitalized in the past 2 years and 25.4% had been treated in an outpatient 
setting (52).  Only 9.4% patients who fit their definition of CA-MRSA lacked a history of health 
care exposure in the two years prior to infection.  However, because risk factors were not taken 
into account when classifying the infections as CA-MRSA, this seems likely to be an 
exaggeration of the effect that contact with health care has on risk of CA-MRSA infection, as an 
unknown number of the “CA-MRSA cases” may have had medical histories that should have 
excluded them from the category.   
Similar to hospital settings, where MRSA is known to spread from person to person, CA-
MRSA has been observed to spread within families and between other groups of people in close 
contact, such as children in day care, prisoners, and athletes in contact sports.  One study found 
that having a family member with MRSA increases the risk of developing MRSA (51).  In 2004, 
of the 632 MRSA isolates analyzed at one hospital (including both HA- and CA-MRSA), 63 
(10%) were among family members and all of these 63 were classified as CA-MRSA.  In a day 
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care setting, after one child developed a serious MRSA middle ear infection, his classmates and 
the day care staff were tested for MRSA carriage (12).  Of the 164 classmates and 9 staff 
members, only 1 classmate was colonized with MRSA.  After further investigation, the 
classmate’s sister was also found to be colonized, and PFGE analysis found that strains for all 
three children were identical to each other and very different from the hospital strains common to 
that geographic area.  While it could not be determined from this case study which child first had 
MRSA colonization, it strongly suggests person to person spread is common in families and at 
day care.  Similarly, PFGE pattern analysis during prison MRSA outbreaks have found that all 
isolates were indistinguishable, suggesting person to person spread (63), as well as among 
athletic teams, both professional and amateur (70).  In sports, people who play positions 
requiring frequent, repetitive contact have the most increased risk of infection due to skin injury.    
3.3.2.5 CA-MRSA contributions to increased morbidity and mortality 
Some severe outbreaks of CA-MRSA have been reported, gaining much attention from 
the media.  One particular outbreak reported in 2000 among members of a Pennsylvania college 
football team resulted in 7 of 10 infected players being hospitalized and treated with intravenous 
antibiotics (40).  Not all infections have these serious outcomes.  However, when comparing the 
effects of CA-MRSA to CA-MSSA, it does appear that methicillin-resistant strains cause greater 
morbidity and mortality.  One study found a statistically significant difference between the 
hospitalization of children with CA-MRSA (62%) than children with CA-MSSA (53%) (64).  
Another surveillance effort of the general population found that 24% of all patients with CA-
MRSA were hospitalized due to infection, and 5% of all CA-MRSA patients required intensive 
care (50).  Similarly, a study by Fridkin and colleagues found that 24% of CA-MRSA patients 
interviewed (136/575) had been hospitalized as a result of their infections (15).                   
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4.0  ORIGINAL RESEARCH 
In September of 2007, while exploring the possibilities for designing a practicum that 
would allow me to investigate an infectious disease-related topic, I contacted the Allegheny 
County Health Department (ACHD).  Dr. LuAnn Brink, the epidemiology manager, brought 
forth an idea involving a project using a database of people who had positive methicillin-
sensitive S. aureus and MRSA cultures that had recently been reported to ACHD.  At that time, 
reporting of MRSA was only mandatory in pediatric cases, but ACHD was about to institute 
across the board mandatory reporting for all positive cultures to gain a clearer picture the 
incidence of infection and the populations most at risk in the county.  Thus, the data that I would 
explore would offer another snapshot of the disease before mandatory reporting.  With the 
approval of ACHD Director, Dr. Bruce Dixon, and the Department of Infectious Diseases and 
Microbiology at the University of Pittsburgh’s Graduate School of Public Health, I undertook 
this project. 
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5.0  METHODS 
Quest Diagnostics provided a database consisting of 1005 people with MRSA (cases) and 
1219 people with methicillin-sensitive S. aureus (MSSA) (controls).  This cohort of 2224 was 
used to conduct a case-control study to determine differences in epidemiology of the infections 
between the two groups.  From this initial group, 19 cases and 7 controls from the Allegheny 
County Correctional Facility were excluded, leaving 986 cases and 1212 controls.  The database 
consists of patients who sought medical care in Allegheny County, Pennsylvania from January 1, 
2007 to August 31, 2007 and had samples that cultured positive for MRSA or MSSA, as 
confirmed by the laboratory results from Quest.  Many of these individuals may have acquired 
the infections outside of healthcare settings.  However, some of the health care providers who 
collected patient samples and sent them to Quest for analysis are long-term care facilities. 
From this database, two random 10% samples of cases and controls were taken using 
Statistical Package for the Social Sciences (SPSS) software.  SPSS selects random samples based 
on a pseudo-random-number generator that depends on a seed value established by the program 
(71). Patients’ phone numbers were located by address using the 2008 COLE Directory.  If the 
address was not located in the Directory, the address’ validity was assessed using the Allegheny 
County Property Tax Assessment website.  If the address did not exist, nothing more was done; 
if the address did exist, yellowpages.com was used in a last attempt to locate a phone number by 
address and name.  Before contacting each patient, the physician who requested the laboratory 
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test was first contacted as a courtesy. Next, each patient was contacted by phone between the 
hours of 10 A.M. and 4 P.M., Monday through Friday during November 2007 to January 2008.  
If a patient was not home, a message requesting that they call the health department was left on 
the machine or with a family member, if possible.  Patients not reached after three call attempts 
were considered non-responsive.  When a patient was reached, they were interviewed using a 
standardized questionnaire that collected basic demographic information, clinical information 
about the infection and treatment received, and risk factors (see Appendix A). If the patient was 
at a long-term care facility at the time when the sample was taken, a member of the medical staff 
with access to patient charts was interviewed for interview completion.      
After the first 10% sample (cases, n=97; controls, n=107) from each group was 
exhausted, a second random 10% sample (cases, n=82; controls, n=89) was taken using SPSS.  
First, any duplicates from the first sample were eliminated.  Then, the same procedure used with 
the first sample group was followed in contacting this second sample of patients.  Once fifty 
questionnaires had been completed for cases and for controls, calling ceased.  Any patients who 
returned calls within a day after the quota was met were interviewed and their answers were 
included in the analysis of results. 
Information collected during interviews was recorded in a deidentified format.  Data was 
entered and counts were calculated using SPSS (Mac Version 16.0). Chi-square and Fisher exact 
tests were used for comparisons of categorical variables and the Student t-test was used for age 
comparisons.  All responses of “unknown” and “not applicable” were excluded from the 
categorical analyses.  All confidence intervals were calculated at 95%.                                
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6.0  RESULTS 
6.1 ANALYSIS OF STUDY POPULATION 
The reporting laboratory provided ages and genders for all individuals in the database.  
This allowed a comparison of all reported cases and controls.  When compared to the controls, 
the MRSA cases were older.  The mean age for MRSA cases was 47.7 (CI 45.9-49.5) years, 
while MSSA controls had an average age of 39.8 (CI 38.3-41.4).  An independent t-test showed a 
statistically significant (p<0.001) mean difference of 7.9 years (CI 5.5-10.2).  This difference in 
means is also reflected in distribution of cases by age.  The MRSA group had a greater 
proportion of older people than the control group.  In fact, 34.4% of MRSA cases were aged 65 
years or older; only 22.1% of MSSA controls were in that same age range.  The age distribution 
of the population affected by MSSA seems be more representative of the local population than 
the age distribution of the population affected by MRSA.  The median age of MSSA controls 
was 39 years, much closer to the estimated median age of 41.7 years for the population of 
Allegheny County than the 50 year median age of MRSA cases (72).  Gender distribution was 
similar between groups.  The MRSA cases consisted of 55.1% females and 44.5% males, while 
MSSA controls consisted of 53.4% females and 46.1% males. 
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6.2 COMPARISON OF STUDY POPULATION TO RESPONDENTS 
Similar to the database population, among the people who completed the questionnaires, 
MRSA respondents (n=54) were older than MSSA respondents (n=50).  However, both groups 
of respondents were older than the database population as a whole (Figures 8 and 9).  The mean 
age differences in the MRSA and MSSA groups were 6.6 and 8.7 years respectively.  The 8.7 
year difference between the MSSA respondents and the database population indicates a 
statistically significant difference in age (p=0.0283); the age difference between MRSA 
respondents and the MRSA database population, however, was not significant (p=0.0986).  
Comparing respondent groups, the average age of MRSA respondents was 54.4 years and MSSA 
respondents was 48.5 years; unlike the database populations, this is not a statistically significant 
difference (p=0.292). The median ages for cases and controls were 57 and 54 years, respectively. 
MRSA respondents consisted of 51.2% males and 48.2% females.  MSSA respondents were 34% 
male and 66% female, a statistically significant imbalance from the expected 1:1 ratio (2-sided 
binomial, p=0.033).  
As shown in Table 3, a large majority of respondents self-classified their race as white or 
Caucasian; other groups represented are black or African American, and Asian.  Nine 
respondents did not indicate a racial group.  A majority of questionnaires were completed by 
patients, but some were answered by patients’ parents or other knowledgeable caretakers, 
patient’s spouses, or medical staff.  In some instances, medical staff answered questionnaires on 
behalf of patients who were deceased or had left the facility.  At the time that the sample was 
taken and sent to Quest, 27.8% of cases and 10% of controls were in non-hospital, non-prison 
community living settings (CLSs).  CLSs include any group or communal living situations that 
are not a hospital or prison, including skilled nursing facilities, assisted living facilities and group 
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homes.  At the time of interview completion, 83.3% of cases and 96% of controls were alive; 
11.1% of cases and 2% of controls were deceased.  Additionally, 5.6% and 2% of cases and 
controls, respectively, had left the CLSs and their vital status at the time of interview could not 
be determined.     
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 A 
B 
Figure 8.  Histograms of ages of MSSA respondents (A) and MSSA database (B). 
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 A 
B 
Figure 9.  Histograms of ages of MRSA respondents (A) and MRSA database (B). 
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 Table 3.  Respondent characteristics. 
 MRSA (n=54) MSSA (n=50) p-value 
Age    
Mean (SD) 54.4 (28.0) 48.5 (28.0) 0.292 
Median 57 54  
Sex    
Male 28 (51.2%)  17 (34.0%) 0.066 
Female 26 (48.2%) 33 (66.0%)  
Race    
White/Caucasian 42 (77.8%) 44 (88%)  
Black/African American 4 (7.4%) 4 (8%)  
Asian 1 (1.8%) 0 (0%)  
Pacific Islander 0 (0%) 0 (0%)  
Native American 0 (0%) 0 (0%)  
Other 0 (0%) 0 (0%)  
No Response 7 (13.0%) 2 (4%)  
Vital Status    
Living  45 (83.3%) 48 (96%) 0.112 
Deceased 6 (11.1%) 1 (2%)  
Unknown 3 (5.6%) 1 (2%)  
Completed by    
Patient 27 (50%) 31 (62%)  
 (95% CI)        (36.8-63.1%) (48.0-74.6%)  
Parent/Caretaker 9 (16.7%) 14 (28%)  
 (95% CI) (8.4-28.4%)  (16.9-41.6%)  
Spouse 2 (3.7%) 0 (0%)  
 (95% CI) (0.6-11.7%) (0.0-5.8%)  
Medical Staff 16 (29.6%) 5 (10%)  
 (95% CI)        (18.6-42.7%)     (3.8-20.8%)  
In CLS When Sample Was Taken   
Yes 15 (27.8%) 5 (10%) 0.481 
No 39 (72.2%) 45 (90%)  
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Evaluating disease characteristics and treatment required for cases and controls (Table 4), 
MRSA samples were more likely to have been taken from the skin than MSSA (70.4% versus 
58.0%).  Most other categories of sample sites seemed similar between the cases and controls, 
except the eye, which was more common in the MSSA group (8.0%) than in the MRSA group 
(1.8%).  As for the infection type, MRSA respondents were more likely to classify their infection 
as an abscess (44.4%) than the MSSA respondents (32.0%).  MRSA respondents were only 
slightly more likely than MSSA respondents to have been prescribed antibiotics as treatment 
(81.5% versus 78.0%).  Five MRSA respondents (9.2%) and three MSSA respondents (6.0%) 
reported being hospitalized as a result of their S. aureus infection. 
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Table 4.  Disease characteristics and treatment. 
 
 MRSA MSSA  p-value 
Sample Source Location   
Skin, General 38 (70.4%) 29 (58.0%) - 
Genital 1 (1.8%) 2 (4.0%) - 
Nares 3 (5.6%) 1 (2.0%) - 
Urine 7 (13.0%) 8 (16.0%) - 
Eye 1 (1.8%) 4 (8.0%) - 
Upper Respiratory 2 (3.7%) 2 (4.0%) - 
Lower Respiratory 0 (0.0%) 1 (2.0%) - 
Blood 1 (1.8%) 0 (0.0%) - 
Other  1 (1.8%) 2 (4.0%) - 
Unknown 0 (0.0%) 1 (2.0%) - 
Type of Infection    
Abscess 24 (44.4%) 16 (32.0%) - 
Folliculitis 2 (3.7%) 0 (0.0%) - 
Cellulitis 0 (0.0%) 0 (0.0%) - 
Other 23 (42.6%) 29 (58.0%) - 
No Infection 4 (7.4%) 3 (6.0%) - 
Unknown 1 (1.8%) 2 (4.0%) - 
Treated with Antibiotics   
Yes 44 (81.5%) 39 (78.0%) 0.198 
No 1 (1.9%) 4 (8.0%)  
Unknown 5 (9.2%) 5 (10.0%)  
N/A 4 (7.4%) 2 (4.0%)  
Hospitalized    
Yes 5 (9.2%) 3 (6.0%) 0.714 
No 43 (79.6%) 45 (90.0%)  
Unknown 2 (3.7%) 0 (0.0%)  
N/A 4 (7.4%) 2 (4.0%)  
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Table 5. Evaluation of risk factors in respondents, where * indicates a p-value<0.05. 
 MRSA MSSA p-value 
Reported Self History of MRSA    
Yes 15 (27.8%) 1 (2.0%) <0.001* 
No 33 (61.1%) 48 (96.0%)  
Unknown 6 (11.1%) 1 (2.0%)  
Household Member or Self with MRSA   
Yes 10 (18.5%) 2 (4.0%) 0.006* 
No 33 (61.1%) 47 (94.0%)  
Unknown 11 (20.4%) 1 (2.0%)  
Household Member or Self in Hospital    
Yes 24 (44.4%) 13 (26.0%) 0.041* 
No 28 (51.8%) 36 (72.0%)  
Unknown 2 (3.7%) 1 (2.0%)  
Household Member or Self in CLS    
Yes 16 (29.6%) 6 (12.0%) 0.032* 
No 38 (70.4%) 43 (86.0%)  
Unknown 0 (0.0%) 1 (2.0%)  
Previous Antibiotic Use    
Yes 31 (57.4%) 25 (50.0%) 0.154 
No 14 (25.9%) 21 (42.0%)  
Unknown 9 (16.7%) 4 (8.0%)  
Outpatient Surgery    
Yes 0 (0.0%) 2 (4.0%) 0.227 
No 51 (94.4%) 45 (90.0%)  
Unknown 3 (5.6%) 3 (6.0%)  
Play Sports    
Yes 9 (16.7%) 7 (14.0%) 0.706 
No 45 (83.3%) 43 (86.0%)  
Piercing    
Yes 0 (0.0%) 1 (2.0%) 0.485 
No 53 (98.1%) 49 (98.0%)  
Unknown 1 (1.9%) 0 (0.0%)  
Tattoo    
Yes 0 (0.0%) 0 (0.0%) - 
No 53 (98.1%) 50 (100.0%)  
Unknown 1 (1.9%) 0 (0.0%)  
Chronic Disease    
Yes 31 (57.4%) 26 (52.0%) 0.580 
Diabetes 10 (18.5%) 7 (14.0%) 0.534 
Skin Condition 5 (9.2%) 3 (6.0%) 0.717 
No 23 (42.5%) 24 (48.0%)  
HCW in Household    
No HCW 34 (63.0%) 40 (80.0%) 0.563 
HCW with Patient Contact 4 (7.4%) 4 (8.0%) (pooled) 
Non-HCW with Patient Contact      0 (0.0%) 1 (2.0%)  
HCW with no Patient Contact 1 (1.8%) 0 (0.0%)  
N/A 15 (27.8%) 5 (10.0%)  
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Examining risk factors for developing MRSA rather than MSSA, there were four that had 
statistical significance.  The first two were having a reported self history of MRSA (p<.001) and 
having a household member or self with MRSA in the year prior to positive culture results 
(p=.006).  The third and fourth risk factors of statistical significance were having a household 
member or self being hospitalized in the year prior to positive culture results (p=.041) and having 
a household member or self in a CLS in the year prior to positive culture (p=.032).  All other risk 
factors evaluated did not show statistical significance (Table 5). 
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7.0  DISCUSSION 
In this retrospective study, there were several potential risk factors identified when 
MRSA-positive patients were compared to MSSA-positive patients.  These factors included 
having a reported self history of MRSA (p<.001), having a member of the household or self with 
a MRSA infection in the year prior to infection (p=.006), having a member of the household or 
self hospitalized in the year prior to infection (p=.041) and having a member of the household or 
self in a CLS in the year prior to infection (p=.032).  None of these identified risk factors were 
novel as they have been previously identified as such in other studies.  Nonetheless, this research 
serves as a confirmation of existing literature. 
We intended to capture a clearer picture of MRSA in the communities of Allegheny 
County, Pennsylvania, outside of hospitals, prisons, and CLSs. However, it is clear that people in 
CLSs with MRSA have been included, with 15 of 54 (27.8%) MRSA-positive respondents and 5 
of 50 (10.0%) MSSA-positive respondents having been in CLSs at the time of the samples being 
taken.  Knowing that a greater number of the MRSA respondents were in CLSs such as nursing 
homes than MSSA respondents, it follows that the MRSA respondents were older than MSSA 
respondents by an average of 5.9 years.  This is similar to the results found by Kuehnert and 
colleagues that age was a risk factor for having MRSA colonization of the nose (22). This 
considerable number of people who were in CLSs may have also influenced the significance of 
risk factors.  Examining the responses of those who said that they or a household member had 
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been hospitalized in the year prior to infection versus those who said that they or a household 
member had been in a CLS in the year prior to infection, 18 of 37 people (48.6%) with 
hospitalization had also been in CLSs.  Of the 20 people in CLSs, 18 of them (90%) had also 
been hospitalized, indicating a great deal of relatedness between the two risk factors.  In fact, if 
people in CLSs at the time of the sample being taken are excluded from the analysis (Table 6), 
hospitalization in the prior year is no longer a significant risk factor for being MRSA-positive 
(p=.410).   
 
Table 6.  Hospitalization as risk factor with CLS patients excluded. 
  MRSA MSSA 
Hospitalization Yes 11 9 
 No 28 35 
 
 
Another set of risk factors that are closely related in this study are having a reported self 
history of MRSA and having a household member or self with MRSA infection in the past year.  
This is similar to the findings of the previously mentioned study, where Crum and colleagues 
found that 13% of all patients included in their study had multiple positive MRSA cultures and 
69% of these cultures represented recurrent infections (51).  In our study, of 104 respondents, 12 
said that they or a household member had a MRSA infection in the year prior to their sample 
being taken.  Of those 12, 10 people identified themselves as having the MRSA infection; only 2 
people did not have the infection themselves.  Of the 16 people who identified themselves as 
having a history of MRSA, 10 said that they had an infection in the last year, 5 had no infection 
in themselves or a household member in the past year, and 1 could not remember.  Thus, the 
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most likely risk factor seems to be that once a person is infected with MRSA for the first time, 
they are more likely to develop another infection in the following year.  However, from the data 
collected, it cannot be determined if the repeated infections that people developed were recurrent 
or at a new site; this could be explored in future work.  The challenge of preventing repeated 
infection has been explored previously.  Researcher J.M. Boyce shared that even after the 
infection clears, colonization at alternate sites of the body may remain, especially in the nose 
where antimicrobial activity may be minimal in the nasal secretions, increasing the risk of repeat 
infections (73).                      
A previous investigation linked MRSA infections to recently receiving a tattoo (39); 
however, in our study, none of the respondents had recently received a tattoo.  Other studies, 
including a meta-analysis (69) linked previous exposure to antibiotics to an increased risk of 
MRSA; the meta-analysis found that people exposed to antibiotic therapy had an almost 2-fold 
chance of acquiring MRSA than non-exposed people.  However, from the data collected for 
Allegheny County, antibiotic use was fairly common in both groups, with no statistically 
significant difference between MRSA and MSSA respondents (p=.154).  Additionally, most 
people interviewed could not recall what types of antibiotics they had taken previously, so no 
subgroup analysis could be performed to analyze which specific antibiotic classes were more 
closely linked with MRSA.  Previous studies had found that quinolones and glycopeptides 
caused the greatest increases in risk of MRSA (69).   
Another risk factor that has been identified in previous research is having chronic 
conditions, especially dermatological conditions (50).  In the Allegheny County data, 31 of 54 
(57.4%) MRSA respondents and 26 of 50 (52.0%) of MSSA respondents reported having 
chronically managed conditions, a non-significant difference (p=.580).  Looking specifically at 
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skin conditions, 5 of 54 (9.2%) MRSA respondents and 3 of 50 (6.0%) MSSA respondents 
reported having skin conditions, which was not a statistical difference (p=.717).  Diabetes is 
another commonly reported chronic condition that has been associated with MRSA (45), but it 
failed to be significant in this study (p=.534).        
One of the biggest limitations of this study is recall bias.  One problem very common in 
the interviews was that people were unsure of many details.  Some people were contacted more 
than a year after the date when the sample was taken.  Thus, some information that could have 
been examined, for example, treatment given for the infection and the length of treatment, was 
not available because many people declined to respond on account of uncertainly.  For people 
with extensive medical histories and many trips to the doctor and hospital, it was hard to recall 
the specifics of their infection and assess the risk factors before the infection, such as 
hospitalization in the year prior.  Some people with repeated infections had difficulty 
remembering the details of that particular incident.  Also, some people were not aware of the 
results of the culture, making it harder to recall what happened.  Because the database included 
all positive culture results—with no differentiation between light growth/colonization and heavy 
growth/infection—some people contacted did not have an infection.  There were even some 
nasal cultures that were taken as surveillance measures in long term care facilities that were 
included in the database.   
A second limitation of this study is the method by which patients were contacted for 
interview.  First, all call attempts were made on weekdays between the hours of 10 A.M. and 4 
P.M.  Messages were left, when possible, and some people called back to complete the interview, 
but the completion of interviews only during these hours made it more difficult to reach middle 
aged working people.  On the other hand, older, retired people  were easier to reach.  Second, 
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only people with published phone numbers were contacted, meaning that anyone who requested 
to be excluded from the directory or pays to have an unpublished phone number could not be 
reached.  If an incorrect address was given, the person also could not be reached.  Third, younger 
people and people who are less established were less likely to be reached.  Because of the wide 
availability and affordability of cellular phones, many younger people may choose not to have a 
phone line at their home.  Even if they choose to have a line, if they live in an apartment or had 
just moved to a new address, it is likely they are not included in the directory.  The sum of all 
these factors is that, despite the steps taken to ensure random samples of the database 
populations, the people completing the interviews for this study did not have the same age 
distribution of the people in the databases. In particular, the youngest age groups were 
underrepresented in both the MRSA and the MSSA respondent groups.  As illustrated in Figures 
8b and 9b, children aged three years and younger were the highest frequency age group for 
people in the MRSA and MSSA databases.  However, of the respondents, represented in Figures 
8a and 9a, older people were represented with the highest frequencies. Thus, the people 
examined in this study were older and may vary in other unknown ways from the database 
population, giving biased results.  One final limitation of this study is that a small number of 
surveys were completed, which resulted in a diminished ability to detect statistical differences. 
In future studies, it would be helpful to exclude any persons who had samples taken while 
they were in CLSs and samples that indicated only colonization rather than infection.  This 
would allow a better characterization of MRSA in the community and a clearer assessment of 
risks.  Some areas that could be explored include comparing the severity of outcomes between 
the MRSA and MSSA groups.  In this study, patients were asked which antibiotics they received 
as treatment and the length of treatment; however, it would be a stronger measure of severity if 
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patients were also asked specifically if they had intravenous (IV) antibiotics, how long their 
hospital stays were, and if intensive care treatment was required.  In this study, some respondents 
did indicate that they received IV antibiotics, but most of those people had many chronic 
conditions and were already living at skilled nursing facilities, so it does not seem appropriate to 
use IV antibiotics as a measure of infection severity.  Another topic that could be pursued in the 
future is tracking and comparing treatments in the MRSA and MSSA groups.  Recall was a 
definite problem in this study because of the lag between samples being taken and follow-up 
calls being made, so future investigations would need to be much more timely to minimize the 
problem.  Many MRSA respondents recalled being switched one or more times to different 
antibiotics, so it would also be interesting to examine which antibiotics area physicians are 
commonly prescribing and how quick they are to follow up with patients after receiving the lab 
results, ensuring that proper treatment is being giving as soon as possible to prevent infection 
progression.                  
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8.0  PUBLIC HEALTH SIGNIFICANCE 
There are several key implications for the effects of MRSA, both in the community and 
hospitals.  As stated earlier, the best estimate of MRSA nasal colonization prevalence in the US 
population, measured in 2001-2002, stands at 0.8% (22).  However, because colonization can 
occur at other sites (23-25), this is likely to be an underestimation of total population prevalence 
at that time.  And, if the trends of the past continue to hold true, it can be assumed that the 
incidence of MRSA infections has continued upward since 2001.  This continual increase in 
MRSA infections, especially outside of hospitals, suggests that the reservoir of MRSA in the 
community is growing with the passage of time.  This idea of a reservoir of MRSA strains not 
associated with hospitals has already been explored by Carleton and her colleagues in the San 
Francisco population (52).  They found that four clonal types were responsible for community-
associated infections in patients who had previous contact with the health care system, either 
through hospitalization or outpatient services.  If these clonal types were hospital-endemic 
strains, it would be expected that they cause a great number of infections that onset in hospitals; 
however, this was not the case.  Thus, Carleton and colleagues have suggested that while the risk 
of MRSA infection is greater in people with health care contact, these people are not acquiring 
the MRSA bacteria during health care visits.  
With the establishment of a CA-MRSA reservoir in the community, it is a real threat that 
these strains could end up establishing themselves in hospitals also.  One previously mentioned 
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study found that MRSA stains carrying SCCmec IV were most likely to be causes of infection 
the community (>95% of MRSA isolates), but were being increasingly found as a cause of 
infection in the hospitals (52% of MRSA isolates) (52).  This suggested that the community 
strains were becoming established in the hospitals and causing infection.       
In addition to this reservoir of CA-MRSA strains, there are still the already existing 
reservoir of HA-MRSA strains found in long-term care facilities and hospitals.  A considerable 
percentage of the US population is hospitalized each year, creating the possibility that HA-
MRSA strains are brought into the community, resulting in infections.  With the number of older 
Americans continuing to increase, the number of people in and out of hospitals and long term 
care facilities will undoubtedly increase also, creating greater rates of infection in the population.  
Since older people also have more chronic diseases and weakened immune systems, they may be 
more likely to serve as carriers of the bacteria for longer periods of time than healthy people.  
This increased length of carriage will create more opportunities for person to person spread, 
which could lead to increased rates of infection. 
All of these increases result in corresponding increases in morbidity and mortality 
resulting from MRSA infection.  As discussed earlier, MRSA often infects the skin and soft 
tissue.  Recent studies have shown that MRSA is the most identifiable cause of acute skin and 
soft tissue infections seen in urban emergency departments(10), indicating the seriousness of 
these infections and the immediate treatment they require.  All MRSA infections, especially if 
not treated appropriately, may become invasive, resulting in long hospital stays, with intensive 
care if necessary.                   
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APPENDIX  
ALLEGHENY COUNTY HEALTH DEPARTMENT MRSA CLINICAL DATA 
QUESTIONNAIRE 
Questionnaire answered by: Patient ___  Parent of Patient ____  Medical Staff ____ Spouse___  
Patient Information      
Sex:   Male ___  Female ___  DOB ___/___/_____ (mm/dd/yyyy) 
 
Race:  White ___   Black ___   Hawaiian Native/Pacific Islander ___ Asian ___ 
American Indian/Alaskan Native ___ Other ___ Refused___ 
 
Ethnicity: Hispanic ___  Non-Hispanic___  Not Answered___   
 
Vital Status: Living ___ Deceased ____  Unknown____ 
 
Medical Information 
When did you notice your infection? ___/___/_____ (mm/dd/yyyy) 
Have you had a MRSA infection in the past?  Yes ___ No___    
What type of infection did you have? Abscess ___   Cellulitis ___    Folliculitis ___   
Other _______________________________ 
Where was the infection located (arm, leg, etc)? __________________________________ 
Were you hospitalized for your infection? Yes ___    No____ 
Was your wound drained? Yes ___    No____ 
Were you treated with antibiotics? Yes ___    No____ 
 If yes, which antibiotic? ___________________ Dose ________ (mg) # Days _____ 
If treatment is completed, are the signs and symptoms gone? Yes ___   No ___ 
 If no, please explain ___________________________________________________ 
 If no, do you plan on seeing your health care provider? Yes ___  No ___ 
Do you play any team sports or participate in an organized fitness activity? (List)  
_________________________________________________________________________ 
If yes, did you continue to play with the infection?  Yes ___  No___ 
Are these sports part of a school program?  Yes ___ No___ 
  If no, location of activity _______________________________________ 
In the year prior to your infection:  
Did anyone in your household have a MRSA infection? Yes ____ No ____  
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 If yes, who? ___________________________________________________ 
Were you, or was anyone in your household incarcerated? Yes ___  No __   
Were you, or was anyone in your household in the hospital? Yes ___ No___    
Were you, or was anyone in your household in any other type of institution?  
Yes ___  No ___ 
  If yes, were you in the institution when you noticed the infection? Y__ N___ 
Did you take antibiotics for any other reason?  Yes ____ No ____ 
  If yes, which antibiotic(s)? ______________________________________ 
In the month prior to your infection: 
 Did you have any outpatient surgery?  Yes ___  No ___ 
 Did you receive a piercing?  Yes ___  No ____ 
 Did you receive a tattoo?  Yes ___ No ____ 
Do you have any ongoing health conditions (eczema or diabetes, e.g.?)  Yes ____  No ____ 
 If yes, please name: ___________________________________________ 
Is anyone in your household, including yourself, a healthcare worker? Yes ___    No___ 
Do you know of anyone else who has or had symptoms similar to yours or who was diagnosed 
with MRSA recently? _______________________________________________ 
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